Here, we discuss the possible involvement

of Hedgehog (Hh) pathway in the cellular regulation and development of cancer in the ovaries. Using the in vitro and in vivo assays developed has facilitated the dissection of the mechanisms behind Hh-driven ovarian cancers formation and growth. Based on recent studies, we propose that the inhibition of Hh signaling may interfere with EX527 spheroid-like structures in ovarian cancers. The components of the Hh signaling may provide novel drug targets, which could be explored as crucial combinatorial strategies for the treatment of ovarian cancers.
Hedgehog(Hh)信号通路可以调控细胞的增殖、迁移和分化等许多过程,并且在胚胎发育时期起重要作用。根据Hh信号通路激活后是否依赖Gli蛋白发挥生物学效应,可分为经典的Hh/Gli信号通路和非经典的Hh信号通路。其中,非经典的Hh信号通路可通过小G蛋白Rho家族信号和钙离子依赖的信号通路调控细胞骨架形态、细胞增殖、凋亡及迁移;经典与非经典的Hh信号通路形成相互联系的信号通路网络介导Hh信号的功能。Hh信号通路的异常持续的激活是许多肿瘤发生、发展的原因之一,Hh信号通路还与肿瘤干细胞的调控、肿瘤血管形成和肿瘤的侵袭转移密切相关,对Hh信号通路的深入研究有利于以Hh信号通路蛋白为靶点的抗肿瘤药物的研发与应用。
目的:合成Hh通路抑制剂vismodegib。方法:以2-氯-5-硝基苯胺为起始原料通过4步反应合成了Hh通路抑制剂vismodegib(2-氯-N-(4-氯-3-(吡啶-2-基)苯基)-4-(甲磺酰基)苯甲酰胺)。结果与结论:目标产物结构经1H-NMR和ESI-MS确证,总收率为51.11%。此路线制备工艺反应条件温和且原料易得,后处理简单,适合于小规模制备的实验室研究。
小细胞肺癌(SCLC)占全部肺癌的15%~25%,从EP方案诞生至今,化疗进展缓慢,无论局限期还是广泛期,预后极差,局限期(LD)SCLC的5年生存率不足10%,广泛期(ES)SCLC的5年生存率微乎其微。靶向药物在肺癌治疗领域的快速进展,已经改变了非小细胞肺癌的治疗模式。虽然众多靶向药物在SCLC的临床研究仍然没有突破,但同样为我们认识SCLC提供了宝贵的科学信息。下面从参与SCLC生长的具有潜在治疗靶点的几条信号通路(图1)谈谈目前SCLC靶向药物研究现状。
肿瘤作为一个复杂的组织,其中的肿瘤干细胞在肿瘤的生长、转移和复发过程中发挥至关重要的作用,因此靶向肿瘤干细胞治疗为肿瘤治愈提供了新的思路.新兴的纳米技术为克服传统药物的局限、有效靶向与杀伤肿瘤干细胞创造了可能.本文概述了肿瘤干细胞的特点,总结了目前靶向肿瘤干细胞的药物研究进展,并对靶向肿瘤干细胞纳米技术的应用进行了总结与展望.
Pancreatic

获悉更多 cancer is the fourth most common cause of cancer deaths worldwide. Although recent therapeutic developments for patients with pancreatic cancer have provided survival benefits, the outcomes for patients with pancreatic cancer remain unsatisfactory. Molecularly targeted cancer therapy has advanced in the past decade with the use of a number of pathways as candidates of therapeutic targets. This review summarizes the molecular features of this refractory disease while focusing on the recent clinical and experimental findings on pancreatic cancer. It also discusses the data supporting current standard clinical outcomes, and offers conclusions that may improve the management of pancreatic cancer in the future.
胰腺癌是一种恶性程度极高的消化道肿瘤,虽然经过数十年的研究,其中位生存期仍仅为6个月,5年生存率不足5%[1]。在西方国家,胰腺癌是导致肿瘤病人死亡的第四大原因,且其发病率呈逐年上升趋势,预计未来10年内将成为肿瘤病人死亡的第二大原因[2]。此外,虽然胰腺癌手术切除率有明显提高,围手术期病死率及并发症发生率显著下降,但治疗效果仍无明显改善[3]。因此,需迫切寻求对胰腺癌有
Pancreatic 点击此处 ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade.